Skip to main content
Publications
Herring WL , Gallagher ME, Shah N, Morse KC, Mladsi D , Dong OM , Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States . Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Moehler M, Wyrwicz L, Chen C, Davenport E , Wang J , Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) vs (C) . Poster presented at the 2024 German Cancer Congress (Deutscher Krebskongress); February 21, 2024. Berlin, Germany. [abstract] Oncol Res Treat. 2024; 41(Supple 1):65. Previously presented at the 2023 ASCO Annual Meeting.
Spelman T, Herring WL , Zhang Y, Tempest M, Pearson I , Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom . Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Todenhofer T, Fizazi K, Shore ND, Tammela T, Kuss I, Le Barre M-A, Mohammed AF, Odom D , Bartsch J , Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC) . Poster presented at the 2020 German Cancer Congress; February 2020. [abstract] Oncol Res Treat. 2020 Feb; 43(Suppl 1):154-5. Previously presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Ensenyat A, Espigares-Tribo G, Machado L, Verdejo FJ, Rodriguez-Arregui R, Serrano J, Miret M, Galindo G, Blanco A, Marsal JR , Sarriegui S, Sinfreu-Bergues X, Serra-Paya N. Metabolic risk management, physical exercise and lifestyle counselling in low-active adults: controlled randomized trial (BELLUGAT) . BMC Public Health. 2017 Mar 14;17(1):257. doi: 10.1186/s12889-017-4144-8
Puig-Barbera J, Tormos A , Sominina A, Burtseva E, Launay O, Ciblak MA, Navtividad-Sancho A, Buigues-Vila A, Martinez-Ubeda S, Mahe C, GIHSN Group. First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season . BMC Public Health. 2014 Jun 5;14:564. doi: 10.1186/1471-2458-14-564.
Otto JL, Baliga P, Sanchez JL, Johns MC, Gray GC, Grieco J, Lescano AG, Mothershead JL, Wagar EJ, Blazes DL, Achila R, Baker W, Blair P, Brown M , Bulimo W, Byarugaba D, Coldren R, Cooper M, Ducatez M, Espinosa B, Ewings P, Guerrero A, Hawksworth T, Jackson C, Klena JD, Kraus S, Macintosh V, Mansour M, Maupin G, Maza J, Montgomery J, Ndip L, Pavlin J, Quintana M, Richard W, Rosenau D, Saeed T, Sinclair L, Smith I, Smith J, Styles T, Talaat M, Tobias S, Tobias S, Vettori J, Villinski J, Wabwire-Mangen F. Training initiatives within the AFHSC-Global Emerging Infections Surveillance and Response System: support for IHR (2005) . BMC Public Health. 2011 Mar 4;11(Suppl 2):S5.